The FDA on February 14, 2018 approved ERLEADA® for patients with Non-Metastatic Castration Resistant Prostate Cancer (NM-CRPC). ERLEADA® is a product of Janssen Biotech Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on February 14, 2018 approved ERLEADA® for patients with Non-Metastatic Castration Resistant Prostate Cancer (NM-CRPC). ERLEADA® is a product of Janssen Biotech Inc.
Advertisement